Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    ARD10248
Show Display Options
Rank Status Study
1 Completed SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients
Condition: Diffuse Large B-cell Lymphoma
Intervention: Drug: SAR3419

Study has passed its completion date and status has not been verified in more than two years.